Nanomedicine delivery, as a multi-lineage and multi-functional designable targeted therapy technology, highlights potential research value in the field of nanomedicine. Nanotechnology can deliver drugs to lesions through specific targeted sites, improve drug efficacy and selectivity, as well as diagnosis through disease marker molecules, and allow integrated nanotechnology to integrate diagnostic and therapeutic functions, enable real-time and accurate diagnosis of the disease and simultaneous treatment, while monitoring efficacy and adjusting the dosing regimen, which provides a brand-new possibility exploration in the diagnosis or treatment of human chronic diseases and malignant tumors. In this paper, the characteristics of lung adenocarcinoma and its current treatment methods are analyzed by literature review and research statistics, and the design concept, targeted therapy mechanism, drug release mode of nanomedicine delivery system (NDDS) and its preclinical and clinical research progress in the treatment of lung adenocarcinoma are further described, and the challenges faced by nanomedicine in clinical translation are discussed. We provide new perspectives in improving cancer treatment options and developing more effective nanomedicines.

Jiangang Chen, Ming Wu, Zhen Yang, Yan Zhang. Application of nano drug delivery system in targeted treatment of lung adenocarcinoma bone metastasis. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 10: 1-11. https://doi.org/10.25236/IJFM.2024.061001.

[1] Hutchinson B D, Shroff G S, Truong M T, et al. Spectrum of lung adenocarcinoma[C]//Seminars in Ultrasound, CT and MRI. WB Saunders, 2019, 40(3): 255-264.

[2] Abbas Z, Rehman S. An overview of cancer treatment modalities[J]. Neoplasm, 2018, 1: 139-157.

[3] Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020. 

[4] Dexter D L, Leith J T. Tumor heterogeneity and drug resistance[J]. Journal of clinical oncology, 1986, 4(2): 244-257.

[5] Gavralidis A, Gainor J F. Immunotherapy in EGFR-mutant and ALK-positive lung cancer: implications for oncogene-driven lung cancer[J]. The Cancer Journal, 2020, 26(6): 517-524. 

[6] Liu Y, Wu A, Li X, et al. A retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients[J]. Asian Journal of Surgery, 2022, 45(1): 367-375. 

[7] Yu M, Duan X, Cai Y, et al. Multifunctional nanoregulator reshapes immune microenvironment and enhances immune memory for tumor immunotherapy[J]. Advanced Science, 2019, 6(16): 1900037. 

[8] He M, Zhang M, Xu T, et al. Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief[J]. Journal of Controlled Release, 2024, 368: 233-250.

[9] Doudican N A, Kumar A, Singh N K, et al. Personalization of cancer treatment using predictive simulation[J]. Journal of translational medicine, 2015, 13: 1-14.

[10] Zhang Q ,Chen X ,Hu Y , et al. BIRC5 Inhibition Is Associated with Pyroptotic Cell Death via Caspase3-GSDME Pathway in Lung Adenocarcinoma Cells[J]. International Journal of Molecular Sciences,2023,24(19).

[11] Nguyen D X, Chiang A C, Zhang X H F, et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis[J]. Cell, 2009, 138(1): 51-62. 

[12] Huang L, Liu A. P001 Discrepancy of Oncogenic Mutations in Bone Metastasis Derived from Lung Adenocarcinoma[J]. Journal of Thoracic Oncology, 2018, 13(12): S1051.

[13] Turner M C, Andersen Z J, Baccarelli A, et al. Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations[J]. CA: a cancer journal for clinicians, 2020, 70(6): 460-479.

[14] Howlader N, Forjaz G, Mooradian M J, et al. The effect of advances in lung-cancer treatment on population mortality[J]. New England Journal of Medicine, 2020, 383(7): 640-649.

[15] Tang Y, Pu X, Yuan X, et al. Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential[J]. Cancer Gene Therapy, 2024: 1-9.

[16] Yanxia X, Liu P, Wei J, et al. Recent progress in targeted therapy for non-small cell lung cancer[J]. Frontiers in Pharmacology, 2023, 14: 1125547.

[17] Zhijun Z, jingkang H. MicroRNA-520e suppresses non-small-cell lung cancer cell growth by targeting Zbtb7a-mediated Wnt signaling pathway[J]. Biochemical and biophysical research communications, 2017, 486(1): 49-56. 

[18] Sackton K L, Dimova N, Zeng X, et al. Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C[J]. Nature, 2014, 514(7524): 646-649. 

[19] Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy[J]. European journal of pharmaceutics and biopharmaceutics, 2015, 93: 52-79.

[20] Barinaga M. Designing therapies that target tumor blood vessels[J]. Science, 1997, 275(5299): 482-484.

[21] Meier P, Legrand A J, Adam D, et al. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity[J]. Nature Reviews Cancer, 2024, 24(5): 299-315.

[22] Khalil FK, Altiok S. Advances in EGFR as a predictive marker in lung adenocarcinoma. Cancer Control. 2015; 22: 193–9.

[23] de Jager V D, Timens W, Bayle A, et al. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries[J]. The Lancet Regional Health–Europe, 2024, 38.

[24] Sun Z, Sun J, Hu H, et al. A novel microRNA miR-4433a-3p as a potential diagnostic biomarker for lung adenocarcinoma[J]. Heliyon, 2024, 10(9).

[25] Lin J J, Shaw A T. Resisting resistance: targeted therapies in lung cancer[J]. Trends in cancer, 2016, 2(7): 350-364.

[26] Gao F, Wu Y, Wang R, et al. Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer[J]. Acta Pharmaceutica Sinica B, 2024, 14(6): 2685-2697. 

[27] Zhang M, Xu C, Wen L, et al. A hyaluronidase-responsive nanoparticle-based drug delivery system for targeting colon cancer cells[J]. Cancer research, 2016, 76(24): 7208-7218. 

[28] Lamprecht A L F, Ubrich N, Yamamoto H, et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease[J]. Journal of Pharmacology and Experimental Therapeutics, 2001, 299(2): 775-781.

[29] Zheng X, Wu Y, Zuo H, et al. Metal nanoparticles as novel agents for lung cancer diagnosis and therapy[J]. Small, 2023, 19(18): 2206624.

[30] Li L, Rashidi L H, Yao M, et al. CuS nanoagents for photodynamic and photothermal therapies: Phenomena and possible mechanisms[J]. Photodiagnosis and photodynamic therapy, 2017, 19: 5-14.

[31] Zanganeh S, Hutter G, Spitler R, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues[J]. Nature nanotechnology, 2016, 11(11): 986-994.

[32] Zhang K, Wu J, Zhao X, et al. Prussian blue/calcium peroxide nanocomposites-mediated tumor cell iron mineralization for treatment of experimental lung adenocarcinoma[J]. ACS nano, 2021, 15(12): 19838-19852.

[33] Tian H X, Mei J, Cao L, et al. Disruption of Iron Homeostasis to Induce Ferroptosis with Albumin‐Encapsulated Pt (IV) Nanodrug for the Treatment of Non‐Small Cell Lung Cancer[J]. Small, 2023, 19(49): 2206688.

[34] Feng J, Xu Z, Dong P, et al. Stimuli-responsive multifunctional metal–organic framework nanoparticles for enhanced chemo-photothermal therapy[J]. Journal of Materials Chemistry B, 2019, 7(6): 994-1004.

[35] Chen J, Irudayaraj J. Quantitative investigation of compartmentalized dynamics of ErbB2 targeting gold nanorods in live cells by single molecule spectroscopy[J]. ACS nano, 2009, 3(12): 4071-4079. 

[36] Karatas H, Aktas Y, Gursoy-Ozdemir Y, et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood–brain barrier and provides neuroprotection[J]. Journal of Neuroscience, 2009, 29(44): 13761-13769.

[37] Vauthier C, Labarre D, Ponchel G. Design aspects of poly (alkylcyanoacrylate) nanoparticles for drug delivery[J]. Journal of drug targeting, 2007, 15(10): 641-663.

[38] Alexis F, Zeng J, Shu W. PEI nanoparticles for targeted gene delivery[J]. CSH Protoc, 2006, 1: 2006.

[39] Naz A, Cui Y, Collins C J, et al. PLGA-PEG nano-delivery system for epigenetic therapy[J]. Biomedicine & Pharmacotherapy, 2017, 90: 586-597.

[40] Kołoczek P, Skórska-Stania A, Cierniak A, et al. Polymeric micelle-mediated delivery of half-sandwich ruthenium (II) complexes with phosphanes derived from fluoroloquinolones for lung adenocarcinoma treatment[J]. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 128: 69-81.

[41] Teong B, Lin C Y, Chang S J, et al. Enhanced anti-cancer activity by curcumin-loaded hydrogel nanoparticle derived aggregates on A549 lung adenocarcinoma cells[J]. Journal of Materials Science: Materials in Medicine, 2015, 26: 1-15.

[42] Chung Y H, Cai H, Steinmetz N F. Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications[J]. Advanced Drug Delivery Reviews, 2020, 156: 214-235.

[43] Narayanan K B, Han S S. Icosahedral plant viral nanoparticles-bioinspired synthesis of nanomaterials/nanostructures[J]. Advances in colloid and interface science, 2017, 248: 1-19.

[44] Narayanan K B, Han S S. Helical plant viral nanoparticles—bioinspired synthesis of nanomaterials and nanostructures[J]. Bioinspiration & Biomimetics, 2017, 12(3): 031001.

[45] Pokorski J K, Steinmetz N F. The art of engineering viral nanoparticles[J]. Molecular pharmaceutics, 2011, 8(1): 29-43. 

[46] Li Y, Yang H, Zong X, et al. Oncolytic Virus‐Like Nanoparticles for Tumor‐Specific Gene Delivery[J]. Advanced Functional Materials, 2024: 2314898.

[47] Capek I. Viral nanoparticles, noble metal decorated viruses and their nanoconjugates[J]. Advances in Colloid and Interface Science, 2015, 222: 119-134. 

[48] Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non–small-cell lung cancer[J]. Journal of Clinical Oncology, 2005, 23(27): 6674-6681. 

[49] Liu Y, Cheng W, et al. Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy[J]. Cancer Nanotechnology, 2023, 14(1): 28.

[50] Bozzuto G, Molinari A. Liposomes as nanomedical devices[J]. International journal of nanomedicine, 2015: 975-999.

[51] Farjadian F, Ghasemi A, Gohari O, et al. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities[J]. Nanomedicine, 2019, 14(1): 93-126.

[52] Rodríguez F, Caruana P, De la Fuente N, et al. Nano-based approved pharmaceuticals for cancer treatment: present and future challenges[J]. Biomolecules, 2022, 12(6): 784.

[53] Gao C, Zhang L, Xu M, et al. Pulmonary delivery of liposomes co-loaded with SN38 prodrug and curcumin for the treatment of lung cancer[J]. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 179: 156-165.

[54] Vaklavas C, Tsimberidou A M, Moulder S, et al. A phase I study dose escalation clinical study of hepatic intraarterial cisplatin, combination systemic intravenous liposomal doxorubicin in patients advanced cancer dominant liver involvement[J]. Journal of Clinical Oncology, 2009, 27(15_suppl): e13512-e13512.

[55] Zhang H. Onivyde for the therapy of multiple solid tumors[J]. OncoTargets and therapy, 2016: 3001-3007.

[56] Liang L, Cen H, Huang J, et al. The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy[J]. Molecular cancer, 2022, 21(1): 186.

[57] Wang W, Fu F, Huang Z, et al. Inhalable biomimetic protein corona-mediated nanoreactor for self-amplified lung adenocarcinoma ferroptosis therapy[J]. ACS nano, 2022, 16(5): 8370-8387.

[58] Liang L, Cen H, Huang J, et al. The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy[J]. Molecular cancer, 2022, 21(1): 186.

[59] Dilliard S A, Siegwart D J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs[J]. Nature Reviews Materials, 2023, 8(4): 282-300.

[60] Dasgupta A, Sofias A M, Kiessling F, et al. Nanoparticle delivery to tumours: from EPR and ATR mechanisms to clinical impact[J]. Nature Reviews Bioengineering, 2024: 1-3.

[61] Tylawsky D E, Kiguchi H, Vaynshteyn J, et al. P-selectin-targeted nanocarriers induce active crossing of the blood–brain barrier via caveolin-1-dependent transcytosis[J]. Nature materials, 2023, 22(3): 391-399.

[62] Ulbrich K, Hola K, Subr V, et al. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies[J]. Chemical reviews, 2016, 116(9): 5338-5431.

[63] Bath J, Turberfield A J. DNA nanomachines[J]. Nature nanotechnology, 2007, 2(5): 275-284.

[64] Zhao P, Yin W, Wu A, et al. Dual‐targeting to cancer cells and M2 macrophages via biomimetic delivery of mannosylated albumin nanoparticles for drug‐resistant cancer therapy[J]. Advanced Functional Materials, 2017, 27(44): 1700403.

[65] Wang J, Zhou T, Liu Y, et al. Application of nanoparticles in the treatment of lung cancer with emphasis on receptors[J]. Frontiers in pharmacology, 2022, 12: 781425.

[66] Veselov V V, Nosyrev A E, Jicsinszky L, et al. Targeted delivery methods for anticancer drugs[J]. Cancers, 2022, 14(3): 622. 

[67] Rad M E, Soylukan C, Kulabhusan P K, et al. Material and design toolkit for drug delivery: state of the art, trends, and challenges[J]. ACS Applied Materials & Interfaces, 2023, 15(48): 55201-55231.

[68] Mudshinge S R, Deore A B, Patil S, et al. Nanoparticles: Emerging carriers for drug delivery[J]. Saudi pharmaceutical journal, 2011, 19(3): 129-141.

[69] Wilczewska A Z, Niemirowicz K, Markiewicz K H, et al. Nanoparticles as drug delivery systems[J]. Pharmacological reports, 2012, 64(5): 1020-1037. 

[70] Patel J, Patel A, Patel M, et al. Introduction to nanoparticulate drug delivery systems[M]// Pharmacokinetics and Pharmacodynamics of Nanoparticulate Drug Delivery Systems. Cham: Springer International Publishing, 2022: 3-23.

[71] Sun X, Zhao P, Lin J, et al. Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system[J]. Cancer Drug Resistance, 2023, 6(2): 390.

[72] Chrastina A, Massey K A, Schnitzer J E. Overcoming in vivo barriers to targeted nanodelivery[J]. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2011, 3(4): 421-437.

[73] Chen H, Ji J, Zhang L, et al. Nanoparticles Coated with Brain Microvascular Endothelial Cell Membranes can Target and Cross the Blood–Brain Barrier to Deliver Drugs to Brain Tumors[J]. Small, 2024: 2306714. 

[74] Souri M, Kiani Shahvandi M, Chiani M, et al. Stimuli-sensitive nano-drug delivery with programmable size changes to enhance accumulation of therapeutic agents in tumors[J]. Drug Delivery, 2023, 30(1): 2186312. 

[75] Juranka P F, Zastawny R L, Ling V. P‐glycoprotein: multidrug‐resistance and a superfamily of membrane‐associated transport proteins[J]. The FASEB journal, 1989, 3(14): 2583-2592.

[76] Xue X, Liang X J. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology[J]. Chinese journal of cancer, 2012, 31(2): 100. 

[77] Da Silva C G, Peters G J, Ossendorp F, et al. The potential of multi-compound nanoparticles to bypass drug resistance in cancer[J]. Cancer chemotherapy and pharmacology, 2017, 80: 881-894.  

[78] Liu J, Cabral H, Mi P. Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release[J]. Advanced Drug Delivery Reviews, 2024: 115239. 

[79] Chavda V P. Nanobased nano drug delivery: a comprehensive review[J]. Applications of targeted nano drugs and delivery systems, 2019: 69-92. 

[80] Ulldemolins A, Seras-Franzoso J, Andrade F, et al. Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics[J]. Cancer Drug Resistance, 2021, 4(1): 44. 

[81] Liu J, Li S, Wang J, et al. Application of nano drug delivery system (NDDS) in cancer therapy: A perspective[J]. Recent patents on anti-cancer drug discovery, 2023, 18(2): 125-132. 

[82] Singh A, Trivedi P, Jain N K. Advances in siRNA delivery in cancer therapy[J]. Artificial cells, nanomedicine, and biotechnology, 2018, 46(2): 274-283.

[83] Lee S J, Son S, Yhee J Y, et al. Structural modification of siRNA for efficient gene silencing[J]. Biotechnology advances, 2013, 31(5): 491-503.

[84] Moncalvo F, Martinez Espinoza M I, Cellesi F. Nanosized delivery systems for therapeutic proteins: Clinically validated technologies and advanced development strategies[J]. Frontiers in bioengineering and biotechnology, 2020, 8: 89. 

[85] Ebrahimi N, Manavi M S, Nazari A, et al. Nano-scale delivery systems for siRNA delivery in cancer therapy: New era of gene therapy empowered by nanotechnology[J]. Environmental Research, 2023: 117263.

[86] Rodríguez F, Caruana P, De la Fuente N, et al. Nano-based approved pharmaceuticals for cancer treatment: present and future challenges[J]. Biomolecules, 2022, 12(6): 784. 

[87] Banerjee D, Cieslar-Pobuda A, Zhu G H, et al. Adding nanotechnology to the metastasis treatment arsenal[J]. Trends in Pharmacological Sciences, 2019, 40(6): 403-418.

[88] Bazhenova L, Tran R, Grilley-Olson J, et al. P1. 03-044 Exploratory Analysis of Lung Cancer Patients in a Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine[J]. Journal of Thoracic Oncology, 2017, 12(11): S1967-S1968.

[89] Kim D W, Kim S Y, Kim H K, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer[J]. Annals of oncology, 2007, 18(12): 2009-2014.

[90] Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics[J]. Theranostics, 2020, 10(10): 4557.

[91] Bobo D, Robinson K J, Islam J, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date[J]. Pharmaceutical research, 2016, 33: 2373-2387.

[92] Zarogoulidis P, Chatzaki E, Porpodis K, et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine[J]. International journal of nanomedicine, 2012: 1551-1572. 

[93] Amararathna M, Goralski K, Hoskin D W, et al. Pulmonary nano-drug delivery systems for lung cancer: current knowledge and prospects[J]. Journal of lung health and diseases, 2019, 3(2).

[94] Veronese F M, Mero A. The impact of PEGylation on biological therapies[J]. BioDrugs, 2008, 22: 315-329.  

[95] Khajeei A, Masoomzadeh S, Gholikhani T, et al. The effect of PEGylation on drugs’ pharmacokinetic parameters; from absorption to excretion[J]. Current Drug Delivery, 2024, 21(7): 978-992. 

[96] Pandit A, Zeugolis D I. Twenty-five years of nano-bio-materials: have we revolutionized healthcare?[J]. Nanomedicine, 2016, 11(9): 985-987.